Portfolio, Program, and Project Management in the Pharmaceutical and Biotechnology Industries

Inbunden, Engelska, 2010

1 859 kr

Beställningsvara. Skickas inom 5-8 vardagar

Fri frakt för medlemmar vid köp för minst 249 kr.

This book describes the way that pharmaceutical projects and programs are currently managed, and offers views from many highly experienced practitioners from within the industry on future directions for drug program management. The book integrates portfolio, program, and project management processes as fundamental for effective and efficient drug product development. Contributing expert authors provide their view of how the projectization approach can be taken forward by the drug industry over the coming years.

Produktinformation

Utgivningsdatum2010-04-16
Mått158 x 218 x 13 mm
Vikt635 g
FormatInbunden
SpråkEngelska
Antal sidor352
FörlagJohn Wiley & Sons Inc
ISBN9780470049662

Tillhör följande kategorier

PETE HARPUM is a Director of Harpum Consulting and has been consulting on Portfolio, Program, and Project Management (P3M) for some ten years. He chairs and contributes to many conferences and symposiums on P3M. Mr. Harpum's other activities include postgraduate lecturing and research on P3M for three world-class universities, and supporting the Association for Project Management, Project Management Institute, and the Drug Information Association in various ways.

Preface ixAcknowledgments xiAbout the Authors xiiiPart One The Life Science Industry Context for Portfolio, Program, and Project Management1. A Review of Project Management in Life Science Industry Sectors 3Thomas R. Dunson2. The Impact of Organizational Size on Drug Project Management 21Eric Morfin3. Drug Development in Biotechnology and How We Can Do It Better 33Susan LinnaPart Two The Portfolio, Program, and Project Management Approaches and Processes4. An Overview of the Organization and Processes of Portfolio, Program, and Project Management 53Pete Harpum5. Portfolio Management in the Pharmaceutical Industry: Balancing Corporate Need with the Reality of Delivering Products to the Market 59John Bennett6. Program Management in Drug Development 85Pauline Stewart-Long7. Project Control 101Martin Powell8. Managing Uncertainty in Drug Projects 135Pete Harpum and Thomas R. Dunson9. Managing Drug Safety Risk 155Thomas R. Dunson and Eric Morfin10. Developing Program Strategy 175Pete Harpum11. Developing Products with “Added Value” 197Trevor J. Brown and Stephen AllportPart Three Integrating the Processes12. Integrated Business Processes to Support Cross-Functional Drug Development 227Martin D. Hynes III13. Integrated Drug Development: From Cradle to Grave and from Lab to Market 239Stephen Allport and Terry Cooke-Davies14. The Development of P3M Capability in Drug Development Organizations 259John Arrowsmith, Patrick Grogan, and Bob Moore15. Implementing Portfolio, Program, and Project Management Best Practices in Drug Development Organizations 287Pete Harpum, Ashley Jamieson, and Inge FisherBibliography 311Index 313